A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells

Cell Cycle

Volumn 13, Issue 16, 2014, Pages 2542-2553

  Kurenova, Elena ^a,b   Ucar, Deniz ^c   Liao, Jianqun ^a   Yemma, Michael ^a   Gogate, Priyanka ^a   Bshara, Wiam ^a   Sunar, Ulas ^a   Seshadri, Mukund ^a   Hochwald, Steven N ^a   Cance, William G ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CureFAKtor Pharmaceuticals   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Angiogenesis; FAK; FAK VEGFR 3 interaction; Melanoma; Protein protein interaction; Scaffold inhibitor; VEGFR3

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CHLOROPYRAMINE; DACARBAZINE; FOCAL ADHESION KINASE; VASCULOTROPIN RECEPTOR 3; BRAF PROTEIN, MOUSE; ENZYME INHIBITOR; ETHYLENEDIAMINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL MOTILITY; CELL VIABILITY; CHEMOSENSITIZATION; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INFANT; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TARGET CELL DESTRUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITORS; ETHYLENEDIAMINES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA; MICE; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84907554049     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2015.941760     Document Type: Article

References (52)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687-701; PMID: 15721476; http://dx.doi.org/10.1016/S0140-6736(05)17951-3
2. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, et al. Genotype-selective combination therapies for melanoma identified by highthroughput drug screening. Cancer Discov 2013; 3:52-67; PMID: 23239741; http://dx.doi.org/10.1158/2159-8290.CD-12-0408
3. Al-Lazikani B, Workman P. Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer Discov 2013; 3:14-9; PMID: 23319765; http://dx.doi.org/10.1158/2159-8290.CD-12-0520
4. Alex J. Eustace SK, Anne-Marie Larkin, Thamir Mahgoub, Dimitrios Tryfonopoulos LOD, Martin Clynes, John Crown, O'Donovan N. Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience 2014; 1:158-66
5. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Jr., Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008; 3:569-85; PMID: 19649148; http://dx.doi.org/10.1586/17469872.3.5.569
6. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1:219-27; PMID: 12086857; http://dx.doi.org/10.1016/S1535-6108(02)00051-X
7. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-60; PMID: 18594512; http://dx.doi.org/10.1038/nature07083
8. Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16:3548-61; PMID: 20606037; http://dx.doi.org/10.1158/1078-0432.CCR-09-2797
9. Clarijs R, Schalkwijk L, Hofmann UB, Ruiter DJ, de Waal RM. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 2002; 62:7059-65; PMID: 12460927
10. Emmett MS, Symonds KE, Rigby H, Cook MG, Price R, Metcalfe C, Orlando A, Bates DO. Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density. BMC Cancer 2010; 10:208; PMID: 20478045; http://dx.doi.org/10.1186/1471-2407-10-208
11. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain RK. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006; 66:8065-75; PMID: 16912183; http://dx.doi.org/10.1158/0008-5472.CAN-06-1392
12. Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, et al. High VEGFR-3-positive circulating lymphatic/ vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res 2009; 15:1741-6; PMID: 19240177; http://dx.doi.org/10.1158/1078-0432.CCR-08-1372
13. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41:375-84; PMID: 20004943; http://dx.doi.org/10.1016/j.humpath.2009.08.016
14. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006; 66:2650-7; PMID: 16510584; http://dx.doi.org/10.1158/0008-5472.CAN-05-1843
15. Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, Laplace MC, Morin G, Gaujarengues F, Dol F, et al. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther 2012; 11:1637-49; PMID: 22584122; http://dx.doi.org/10.1158/1535-7163.MCT-11-0866-T
16. Norrmen C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation 2011; 123:1335-51; PMID: 21444892; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.704098
17. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Therap 2006; 5:1136-44; PMID: 16731745; http://dx.doi.org/10.1158/1535-7163.MCT-06-0084
18. Garces CA, Kurenova EV, Golubovskaya VM, Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 2006; 66:1446-54; PMID: 16452200; http://dx.doi.org/10.1158/0008-5472.CAN-05-1661
19. Cox BD, Natarajan M, Stettner MR, Gladson CL. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 2006; 99:35-52; PMID: 16823799; http://dx.doi.org/10.1002/jcb.20956
20. Lechertier T, Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. J Pathol 2012; 226:404-12; PMID: 21984450; http://dx.doi.org/10.1002/path.3018
21. Zhao X, Guan J-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliver Rev 2011; 63:610-5; PMID: 21118706; http://dx.doi.org/10.1016/j.addr.2010.11.001
22. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2010; 2:516-28; PMID: 21154724; http://dx.doi.org/10.1002/emmm.201000106
23. Wary KK, Kohler EE, Chatterjee I. Focal adhesion kinase regulation of neovascularization. Microvasc Res 2012; 83:64-70; PMID: 21616084; http://dx.doi.org/10.1016/j.mvr.2011.05.002
24. Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA, Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem 2009; 52:4716-24; PMID: 19610651; http://dx.doi.org/10.1021/jm900159g
25. Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, Cance WG. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005; 15:357-62; PMID: 16179862; http://dx.doi.org/10.1097/00008390-200510000-00003
26. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003; 162:1431-9; PMID: 12707026; http://dx.doi.org/10.1016/S0002-9440(10)64276-9
27. Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 2013; 126:21-9; PMID: 23516327; http://dx.doi.org/10.1242/jcs.120907
28. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Invest Drugs 2010; 19:777-88; PMID: 20465362; http://dx.doi.org/10.1517/13543784.2010.489548
29. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, et al. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis 2013; 30:579-94; PMID: 23275034; http://dx.doi.org/10.1007/s10585-012-9562-5
30. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 2012; 30:1527-33; PMID: 22454420; http://dx.doi.org/10.1200/JCO.2011.38.9346
31. Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer Agents Med Chem 2011; 11:593-9; PMID: 21787277; http://dx.doi.org/10.2174/187152011796817727
32. Cance WG, Kurenova E, Marlowe T, Golubovskaya V. Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal 2013; 6:10-15; http://dx.doi.org/10.1126/scisignal.2004021
33. Akasaka T, van Leeuwen RL, Yoshinaga IG, Mihm MC, Jr., Byers HR. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 1995; 105:104-8; PMID: 7615962; http://dx.doi.org/10.1111/1523-1747.ep12313396
34. Xu LH, Yang X, Craven RJ, Cance WG. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 1998; 9:999-1005; PMID: 9869300
35. Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. Focal adhesion kinase activated by beta(4) integrin ligation to mCLCA1 mediates early metastatic growth J Biol Chem 2002; 277:34391-400; PMID: 12110680; http://dx.doi.org/10.1074/jbc.M205307200
36. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005; 65:9851-60; PMID: 16267008; http://dx.doi.org/10.1158/0008-5472.CAN-05-2172
37. Hess AR, Hendrix MJ. Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006; 5:478-80; PMID: 16552181; http://dx.doi.org/10.4161/cc.5.5.2518
38. Abbi S, Guan JL. Focal adhesion kinase: protein interactions and cellular functions. Histol Histopathol 2002; 17:1163-71; PMID: 12371144
39. Fan H, Zhao X, Sun S, Luo M, Guan J-L. Focal adhesion kinase scaffolding function to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo. J Biol Chem 2013; 288:3322-33; PMID: 23255596; http://dx.doi.org/10.1074/jbc.M112.420497
40. Kaneda T, Sonoda Y, Ando K, Suzuki T, Sasaki Y, Oshio T, Tago M, Kasahara T. Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett 2008; 270:354-61; PMID: 18606490; http://dx.doi.org/10.1016/j.canlet.2008.05.042
41. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002; 8:3728-33; PMID: 12473582
42. Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005; 106:3423-31; PMID: 16076871; http://dx.doi.org/10.1182/blood-2005-04-1388
43. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006; 25:5969-84; PMID: 16682956
44. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22:3172-9; PMID: 12789293; http://dx.doi.org/10.1038/sj.onc.1206457
45. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma. Clin Cancer Res 2009; 15:3495-502; PMID: 19447871; http://dx.doi.org/10.1158/1078-0432.CCR-08-2407
46. Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, Gu YH. Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncol Lett 2013; 6:69-74; PMID: 23946779
47. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Augustin HG, Schadendorf D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010; 207:491-503; PMID: 20194633; http://dx.doi.org/10.1084/jem.20091846
48. Haskell H, Natarajan M, Hecker TP, Ding Q, Stewart J, Grammer JR, Gladson CL. Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells. Clin Cancer Res 2003; 9:2157-65; PMID: 12796381
49. Chou T-C. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res 2010; 70:440-6; PMID: 20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
50. Seshadri M, Sacadura N, Coulthard T. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging. Angiogenesis 2011; 14:491-501; PMID: 21901534; http://dx.doi.org/10.1007/s10456-011-9233-1
51. Sunar U, Rohrbach D, Rigual N, Tracy E, Keymel K, Cooper MT, Baumann H, Henderson BH. Monitoring photobleaching and hemodynamic responses to HPPH-mediated photodynamic therapy of head and neck cancer: a case report. Opt Express 2010; 18:14969-78; PMID: 20639983; http://dx.doi.org/10.1364/OE.18.014969
52. Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, et al. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle 2012; 11:3250-9; PMID: 22894899; http://dx.doi.org/10.4161/cc.21611